角膜移植免疫排斥反应局部治疗的研究进展  

Recent advances in local anti-rejection treatment of corneal transplantation

作　　者：张旺[1] 赵敏[1] 

机构地区：[1]重庆医科大学附属第一医院眼科,重庆市400016

出　　处：《眼科新进展》2015年第8期795-800,共6页Recent Advances in Ophthalmology

摘　　要：角膜移植术后免疫排斥反应是角膜移植失败的重要原因。角膜移植术后局部抗排斥治疗以其用药剂量小而局部药物浓度高、副反应少,具有巨大的发展潜力。本文主要回顾了近年来用于局部抗角膜移植排斥反应药物的相关研究,分析该类药物的作用机制,并评价其疗效及安全性,探讨局部用药防治角膜移植术后免疫排斥反应的发展方向。Graft rejection is the most important reason for corneal transplantation failure. Local anti-rejection treatment after corneal transplantation has huge development potential resulting from its lower dosage, high local concentration, and less side effects. This article mainly reviews the researches of topical drugs administrated to corneal transplantation in recent years, analyzes their mechanism of action, and evaluates their efficacy and safety to explore the development direction of local anti-rejection treatment.

关 键 词：角膜移植 免疫排斥反应 免疫抑制剂 血管生成抑制剂 

分 类 号：R779.65[医药卫生—眼科]